Why These Two Stocks Surged: Unity and Celsius
Throughout the last six months, gaming firm Unity Software (U) traded in a range of $20 - $25. U stock broke out last week after posting quarterly earnings.On Feb. 20, Unity reported a 25.0% Y/Y drop in revenue, to $457.1 million. Non-GAAP EPS was a $0.30 loss. Create Solutions revenue fell by around half, to $152 million. This is a result of the negative lingering impact of runtime fees on gaming creators. Investors need to wait for Unity to report a rebound in this figure.Grow Solutions held up well, with revenue at $305 million, compared to $319 million last year. Unity managed to fend off the competition from AppLovin (APP) in the mobile sector.Unity posted a positive free cash flow of $286 million in the quarter. The firm is managing costs and focusing on the core gaming engine development.In the drink industry, Celsius (CELH) rallied by nearly 30%. The firm posted Q4 revenue falling by 4.3% Y/Y to $332.2 million. However, the acquisition of Alani Nu overshadowed the weak results. Investors expect the Alani will reignite Celsius’s growth. Alani has a unique customer base. For example, it has a 92% female following on social media. This suggests that the acquisition has little overlap with its core business. As a result, the combined company will have great portfolios in the energy drink category.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


